Apremilast: A dermatologic perspective
Apremilast is an oral phosphodiesterase 4 inhibitor, now approved by the Food and Drug Administration in the management of psoriatic arthropathy (PsA). As biologic therapy is associated with significant amounts of adverse effects, newer treatment options with an efficacious outcome, sans the toxicit...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
| Series: | Indian Journal of Drugs in Dermatology |
| Subjects: | |
| Online Access: | http://www.ijdd.in/article.asp?issn=2455-3972;year=2016;volume=2;issue=2;spage=75;epage=82;aulast=Bubna |